Tags

Type your tag names separated by a space and hit enter

Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
J Nucl Med 2012; 53(3):378-84JN

Abstract

The objectives of this study were to examine the effective dose range and the test-retest reliability of florbetapir F 18 using, first, visual assessment by independent raters masked to clinical information and, second, semiautomated quantitative measures of cortical target area to cerebellum standardized uptake value ratios (SUVr) as primary outcome measures. Visual ratings of PET image quality and tracer retention or β-amyloid (Aβ) binding expressed as SUVrs were compared after intravenous administration of either 111 MBq (3 mCi) or 370 MBq (10 mCi) of florbetapir F 18 in patients with Alzheimer's disease (AD) (n = 9) and younger healthy controls (YHCs) (n = 11). In a separate set of subjects (AD, n = 10; YHCs, n = 10), test-retest reliability was evaluated by comparing intrasubject visual read ratings and SUVrs for 2 PET images acquired within 4 wk of each other.

RESULTS

There were no meaningful differences between the 111-MBq (3-mCi) and 370-MBq (10-mCi) dose in the visual rating or SUVr. The difference in the visual quality across 111 and 370 MBq showed a trend toward lower image quality, but no statistical significance was achieved (t test; t(1) = -1.617, P = 0.12) in this relatively small sample of subjects. At both dose levels, visual ratings of amyloid burden identified 100% of AD subjects as Aβ-positive and 100% of YHCs as Aβ-negative. Mean intrasubject test-retest variability for cortical average SUVrs with the cerebellum as a reference over the 50- to 70-min period was 2.4% ± 1.41% for AD subjects and 1.5% ± 0.84% for controls. The overall SUVr test-retest correlation coefficient was 0.99. The overall κ-statistic for test-retest agreement for Aβ classification of the masked reads was 0.89 (95% confidence interval, 0.69-1.0).

CONCLUSION

Florbetapir F 18 appears to have a wide effective dose range and a high test-retest reliability for both quantitative (SUVr) values and visual assessment of the ligand. These imaging performance properties provide important technical information on the use of florbetapir F 18 and PET to detect cerebral amyloid aggregates.

Authors+Show Affiliations

Avid Radiopharmaceuticals, Inc., Philadelphia, PA 19104, USA. joshi@avidrp.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22331215

Citation

Joshi, Abhinay D., et al. "Performance Characteristics of Amyloid PET With Florbetapir F 18 in Patients With Alzheimer's Disease and Cognitively Normal Subjects." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 53, no. 3, 2012, pp. 378-84.
Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53(3):378-84.
Joshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C. H., ... Skovronsky, D. M. (2012). Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 53(3), pp. 378-84. doi:10.2967/jnumed.111.090340.
Joshi AD, et al. Performance Characteristics of Amyloid PET With Florbetapir F 18 in Patients With Alzheimer's Disease and Cognitively Normal Subjects. J Nucl Med. 2012;53(3):378-84. PubMed PMID: 22331215.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. AU - Joshi,Abhinay D, AU - Pontecorvo,Michael J, AU - Clark,Chrisopher M, AU - Carpenter,Alan P, AU - Jennings,Danna L, AU - Sadowsky,Carl H, AU - Adler,Lee P, AU - Kovnat,Karel D, AU - Seibyl,John P, AU - Arora,Anupa, AU - Saha,Krishnendu, AU - Burns,Jason D, AU - Lowrey,Mark J, AU - Mintun,Mark A, AU - Skovronsky,Daniel M, AU - ,, Y1 - 2012/02/13/ PY - 2012/2/15/entrez PY - 2012/2/15/pubmed PY - 2012/4/24/medline SP - 378 EP - 84 JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine JO - J. Nucl. Med. VL - 53 IS - 3 N2 - UNLABELLED: The objectives of this study were to examine the effective dose range and the test-retest reliability of florbetapir F 18 using, first, visual assessment by independent raters masked to clinical information and, second, semiautomated quantitative measures of cortical target area to cerebellum standardized uptake value ratios (SUVr) as primary outcome measures. Visual ratings of PET image quality and tracer retention or β-amyloid (Aβ) binding expressed as SUVrs were compared after intravenous administration of either 111 MBq (3 mCi) or 370 MBq (10 mCi) of florbetapir F 18 in patients with Alzheimer's disease (AD) (n = 9) and younger healthy controls (YHCs) (n = 11). In a separate set of subjects (AD, n = 10; YHCs, n = 10), test-retest reliability was evaluated by comparing intrasubject visual read ratings and SUVrs for 2 PET images acquired within 4 wk of each other. RESULTS: There were no meaningful differences between the 111-MBq (3-mCi) and 370-MBq (10-mCi) dose in the visual rating or SUVr. The difference in the visual quality across 111 and 370 MBq showed a trend toward lower image quality, but no statistical significance was achieved (t test; t(1) = -1.617, P = 0.12) in this relatively small sample of subjects. At both dose levels, visual ratings of amyloid burden identified 100% of AD subjects as Aβ-positive and 100% of YHCs as Aβ-negative. Mean intrasubject test-retest variability for cortical average SUVrs with the cerebellum as a reference over the 50- to 70-min period was 2.4% ± 1.41% for AD subjects and 1.5% ± 0.84% for controls. The overall SUVr test-retest correlation coefficient was 0.99. The overall κ-statistic for test-retest agreement for Aβ classification of the masked reads was 0.89 (95% confidence interval, 0.69-1.0). CONCLUSION: Florbetapir F 18 appears to have a wide effective dose range and a high test-retest reliability for both quantitative (SUVr) values and visual assessment of the ligand. These imaging performance properties provide important technical information on the use of florbetapir F 18 and PET to detect cerebral amyloid aggregates. SN - 1535-5667 UR - https://www.unboundmedicine.com/medline/citation/22331215/Performance_characteristics_of_amyloid_PET_with_florbetapir_F_18_in_patients_with_alzheimer's_disease_and_cognitively_normal_subjects_ L2 - http://jnm.snmjournals.org/cgi/pmidlookup?view=long&pmid=22331215 DB - PRIME DP - Unbound Medicine ER -